QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
NASDAQ:DNLI

Denali Therapeutics Stock Forecast, Price & News

$44.37
+1.34 (+3.11%)
(As of 12/7/2021 04:00 PM ET)
Add
Compare
Today's Range
$43.13
$44.93
50-Day Range
$42.59
$55.02
52-Week Range
$41.10
$93.94
Volume
417,910 shs
Average Volume
558,275 shs
Market Capitalization
$5.42 billion
P/E Ratio
316.95
Dividend Yield
N/A
Beta
1.79
30 days | 90 days | 365 days | Advanced Chart
Receive DNLI News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Denali Therapeutics logo

About Denali Therapeutics

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Headlines

Denali Therapeutics (NASDAQ:DNLI) Sets New 12-Month Low at $43.69
November 29, 2021 |  americanbankingnews.com
Denali Therapeutics (NASDAQ:DNLI) Reaches New 52-Week Low at $43.81
November 23, 2021 |  americanbankingnews.com
Denali (DNLI) Stock Up Despite Wider-Than-Expected Q3 Loss
November 8, 2021 |  finance.yahoo.com
Denali Therapeutics Insider Trades $500K In Company Stock
October 7, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DNLI
Fax
N/A
Employees
291
Year Founded
N/A

Sales & Book Value

Annual Sales
$335.66 million
Cash Flow
$0.66 per share
Book Value
$8.29 per share

Profitability

Net Income
$71.14 million
Pretax Margin
8.61%

Debt

Price-To-Earnings

Miscellaneous

Free Float
101,365,000
Market Cap
$5.42 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/07/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

MarketRank

Overall MarketRank

2.25 out of 5 stars

Medical Sector

349th out of 1,394 stocks

Biological Products, Except Diagnostic Industry

55th out of 202 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions

Is Denali Therapeutics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Denali Therapeutics stock.
View analyst ratings for Denali Therapeutics
or view top-rated stocks.

How has Denali Therapeutics' stock been impacted by COVID-19?

Denali Therapeutics' stock was trading at $16.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DNLI stock has increased by 162.9% and is now trading at $44.37.
View which stocks have been most impacted by COVID-19
.

When is Denali Therapeutics' next earnings date?

Denali Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Denali Therapeutics
.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.69) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.46) by $0.23. The business had revenue of $5.29 million for the quarter, compared to the consensus estimate of $30.28 million. Denali Therapeutics had a net margin of 8.38% and a trailing twelve-month return on equity of 2.72%. The firm's quarterly revenue was down 43.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.54) earnings per share.
View Denali Therapeutics' earnings history
.

What price target have analysts set for DNLI?

8 Wall Street analysts have issued 1 year price objectives for Denali Therapeutics' stock. Their forecasts range from $70.00 to $111.00. On average, they expect Denali Therapeutics' stock price to reach $93.29 in the next twelve months. This suggests a possible upside of 110.2% from the stock's current price.
View analysts' price targets for Denali Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Denali Therapeutics' key executives?

Denali Therapeutics' management team includes the following people:

What is Ryan Watts' approval rating as Denali Therapeutics' CEO?

1 employees have rated Denali Therapeutics CEO Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among Denali Therapeutics' employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Denali Therapeutics own?

When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (12.34%), Crestline Management LP (6.31%), BlackRock Inc. (6.19%), Temasek Holdings Private Ltd (4.40%), Credit Suisse AG (1.62%) and Casdin Capital LLC (1.39%). Company insiders that own Denali Therapeutics stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends for Denali Therapeutics
.

Which institutional investors are selling Denali Therapeutics stock?

DNLI stock was sold by a variety of institutional investors in the last quarter, including Crestline Management LP, Wasatch Advisors Inc., Invesco Ltd., Jennison Associates LLC, Baillie Gifford & Co., Bamco Inc. NY, Marshall Wace LLP, and Two Sigma Investments LP. Company insiders that have sold Denali Therapeutics company stock in the last year include Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Steve E Krognes, and Vicki L Sato.
View insider buying and selling activity for Denali Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Denali Therapeutics stock?

DNLI stock was acquired by a variety of institutional investors in the last quarter, including Pathway Capital Management LP, Temasek Holdings Private Ltd, BlackRock Inc., Goldman Sachs Group Inc., Hamilton Lane Advisors LLC, Dimensional Fund Advisors LP, Moors & Cabot Inc., and Skandinaviska Enskilda Banken AB publ .
View insider buying and selling activity for Denali Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Denali Therapeutics?

Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $44.37.

How much money does Denali Therapeutics make?

Denali Therapeutics has a market capitalization of $5.42 billion and generates $335.66 million in revenue each year. The company earns $71.14 million in net income (profit) each year or $0.14 on an earnings per share basis.

How many employees does Denali Therapeutics have?

Denali Therapeutics employs 291 workers across the globe.

What is Denali Therapeutics' official website?

The official website for Denali Therapeutics is www.denalitherapeutics.com.

Where are Denali Therapeutics' headquarters?

Denali Therapeutics is headquartered at 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (615) 866-8548 or via email at [email protected].


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.